**TCWP CALL FOR PARTICIPATION**

**SFAST Leiden Data Office**

*A cross-sectional study between the TCWP and the Nurse Group of the EBMT*

**Inclusion criteria:**
- Age ≥ 18 years
- Time of follow up 2 till 4 and 14 till 16 years post Allogeneic HSCT
- Ability to read and write in English, French, German, Italian or Dutch
- No cognitive impairment

**Current Status:**
Six sites are actively enrolling and another six are busy with the EC submissions. 89 patients have been enrolled so far of the 311 are required.

**Primary objective:**
1. To explore patients’ and their partners’ opinions on their sexual functioning 2 till 4 and 14 till 16 years post Allogeneic HSCT
2. To evaluate if discussion, adequate help or counseling with regard to sexual function between the healthcare provider and the survivor has taken place

**PI:**
Corien Eeltink and Jacqui Stringer

**Survey:**
Evaluate the current clinical practice in EBMT centres concerning the use of ATG as GVHD prophylaxis after allogeneic HCT due to haematological malignancies

**Primary objective:**
1. To document the clinical use of ATG as GVHD prevention in EBMT centres
2. To document the clinical use of ATG as GVHD prophylaxis

**Inclusion Criteria:**
- ATG use as GVHD prophylaxis

**Current status:**
Up to 09/02/2019 105 centers have responded, hoping to collect at least 100 responses

**TCWP Meetings**

**EBMT Annual Meeting Frankfurt**
Monday, 25th March, 11:00-12:30
Room: Conclusio 1+2

**EBMT Annual Meeting Frankfurt**
Tuesday, 26th March, 07:00 - 09:00
Room: Illusion 3

**1st EBMT GVHD Summit in Warsaw, Poland**
16th May – 18th May 2019

**New TCWP Studies**

**TCWP Paris Data Office**

**SOS/VOD Paris Data Office**

*Non interventional study: EASIX to predict alloSCT outcome.*

**Primary objective:**
To estimate the prognostic ability of EASIX before conditioning (i.e. at the day of hospital admission for alloSCT), at day of transplantation, at day 14 and at day 28 on 1-year NRM.

**Inclusion criteria:**
- First alloSCT in children and adults with PBSCs (all donor types).
- Previous autoSCT is not an exclusion criterion.
- Patients with acute leukaemia, MDS, MPN or lymphoma (all disease stages).
- Myeloablative and dose-reduced conditioning (all types of GVHD prophylaxis).

**Expected study period:**
February 1st 2018. It is expected that recruitment will be closed by May 31st 2019. Follow up will be till day +365 after alloSCT. So far 108 registrations and 60 D-1-00 questionnaires have been collected.

**PI:**
Tapani Ruutu.

**Primary objective:**
To document incidence and frequency of infectious and non-infectious complications after posttransplant cyclophosphamide-based haploSCT.

**Inclusion Criteria:**
- Adult patients (>18y old at time of transplant).
- Patients in whom T cell-replete haploidentical stem cell transplantation with posttransplant cyclophosphamide has been performed between November 2017 and December 2019.

**Current status:**
9 centres participating, 76 patients enrolled, hoping to reach 300

**Expected study period:**
2017-2021 (registration: 1st November 2017-31st December 2019, 2 years follow up).

**Non interventional study:**
*Non interventional observational study on the incidence, severity, management and outcome of sinusoidal obstruction syndrome/ re-occlusive disease of the liver in allogeneic haematopoietic stem cell transplantation in adult patients.*

**PI:**
Jaroslaw Bilinski.

**Primary objective:**
To describe the clinical efficacy of FMT used for treatment of GVHD in a retrospective series of patients. Clinical efficacy is defined as clinical response (complete and partial response) at day 28 after start of FMT.

**Study population:**
Adult patients after alloHCT who developed gastrointestinal graft versus host disease and were treated with FMT.

**Current status:**
So far 24 patients identified